Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > fda max

: 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison

or 60 mg/d typical

or 80 mg/d

Use the filters below to narrow your results.

Atorvastatin (1) · Benazepril (1) · Esomeprazole (1) · Lisinopril (1) · Methimazole (thiamazole) (1) · Pantoprazole (1) · Pravastatin (1) · Telmisartan (1)

Lipitor (1) · Lotensin (1) · Micardis (1) · Nexium, Nexium 24HR (OTC) (1) · Pravachol (1) · Protonix (1) · Tapazole; outside US Mercazole (1) · Zestril, Prinivil, Qbrelis (1)

[[:Category:ACE_inhibitors|ACE inhibitor]] (2) · [[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (1) · [[:Category:Antihypertensives|Antihypertensive]] (3) · [[:Category:Antisecretory_agents|Gastric acid suppressant]] (2) · [[:Category:Antithyroid_agents|Antithyroid agent]] (1) · [[:Category:Lipid-lowering_agents|Lipid-lowering agent]] (2) · [[:Category:Proton_pump_inhibitors|Proton pump inhibitor (PPI)]] (2) · [[:Category:Statins|Statin]] (2) · [[:Category:Thionamides|Thionamide]] (1)

None (1) · '"`UNIQ--vote-00000053-QINU`"' Also raises bradykinin, contributing to vasodilation and the characteristic dry cough. Renally cleared, unmetabolized; dose-adjust by eGFR'"`UNIQ--ref-00000054-QINU`"'. (1) · '"`UNIQ--vote-00000117-QINU`"' Compared with omeprazole, pantoprazole has a more linear pharmacokinetic profile and is metabolized predominantly via CYP2C19 with CYP3A4 contribution; less CYP2C19-driven drug interaction with clopidogrel than omeprazole'"`UNIQ--ref-00000118-QINU`"'. (1) · '"`UNIQ--vote-000003D1-QINU`"' SLCO1B1 polymorphism affects exposure but is most clinically actionable for simvastatin'"`UNIQ--ref-000003D2-QINU`"'. (1) · '"`UNIQ--vote-000008E1-QINU`"' Like omeprazole, it is an acid-activated prodrug that covalently and irreversibly binds the H+/K+ ATPase. CYP2C19 PGx remains clinically relevant for both'"`UNIQ--ref-000008E2-QINU`"'. (1) · '"`UNIQ--vote-00000A1D-QINU`"' Like other ACE inhibitors, it raises bradykinin (driving the dry cough and rare angioedema). Renally cleared; dose-adjust in renal impairment'"`UNIQ--ref-00000A1E-QINU`"'. (1) · '"`UNIQ--vote-00000AEA-QINU`"' The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence'"`UNIQ--ref-00000AEB-QINU`"'. (1) · '"`UNIQ--vote-00000ECD-QINU`"' Agranulocytosis is the most-feared adverse effect (~0.3%, usually first 90 days of treatment; warn patients to seek urgent CBC for fever or severe sore throat). Hepatotoxicity is class-recognized but more often associated with PTU'"`UNIQ--ref-00000ECE-QINU`"'. (1)

10 mg PO once daily (5 mg if on a diuretic); titrate to 40 mg (1) · 10-20 mg PO once daily (1) · 10-40 mg PO daily depending on hyperthyroidism severity; titrate by clinical and biochemical response (target TSH/free T4) (1) · 20-40 mg PO once daily, 30-60 minutes before breakfast (1) · 40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions) (1) · 40 mg PO once daily; titrate to 80 mg (1) · 40 mg PO or IV once daily (1) · 5-10 mg PO once daily (2.5 mg in heart failure, hyponatremia, or volume depletion) (1)

10 mg, 20 mg, 40 mg, 80 mg tablets (2) · 2.5, 5, 10, 20, 30, 40 mg tablets; 1 mg/mL oral solution (1) · 20 mg, 40 mg delayed-release tablets; 40 mg IV vial; oral suspension 40 mg/packet (1) · 20, 40 mg delayed-release capsules; 2.5, 5, 10, 20, 40 mg oral suspension packets; 20, 40 mg IV (1) · 20, 40, 80 mg tablets (1) · 5, 10 mg tablets (1) · 5, 10, 20, 40 mg tablets (1)

IV (2) · Oral (8)

2-3 hours per dose; full acid suppression after 3-5 days (1) · Acid suppression within hours; full effect after 3-5 days of dosing (1) · Biochemical improvement within 2-4 weeks; full euthyroid state 6-12 weeks (1) · BP effect within 1-2 weeks (1) · BP lowering within 1 hour; max at 6 hours (1) · BP lowering within 1 hour; max effect at 6 hours (1) · LDL lowering at 2 weeks, max by 4 weeks (1) · LDL lowering at 2 weeks, max by 4 weeks; cardiovascular benefit months to years (1)

24 hours (5) · 24+ hours (irreversible enzyme binding) (1) · 24-48 hours per dose (1) · 24-72 hours per dose (irreversible enzyme binding) (1)

10-11 hours (benazeprilat, the active metabolite)'"`UNIQ--ref-00000A22-QINU`"' (1) · 14 hours (parent); 20-30 hours including active ortho- and para-hydroxylated metabolites'"`UNIQ--ref-0000001B-QINU`"' (1) · ~1 hour (plasma); pharmacodynamic effect persists 24+ hours'"`UNIQ--ref-0000011D-QINU`"' (1) · ~1.5 hours (plasma); pharmacodynamic effect 24+ hours via target turnover'"`UNIQ--ref-000008E8-QINU`"' (1) · ~12 hours (effective); terminal half-life is biphasic'"`UNIQ--ref-00000059-QINU`"' (1) · ~2-3 hours (parent); pharmacodynamic effect 24 hours via target turnover'"`UNIQ--ref-000003D5-QINU`"' (1) · ~24 hours (longest of the ARB class; suits patients with morning BP surge)'"`UNIQ--ref-00000AEE-QINU`"' (1) · ~4-6 hours (plasma); intrathyroidal accumulation gives a much longer functional duration'"`UNIQ--ref-00000ED3-QINU`"' (1)

42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"' (1) · ~14% (extensive hepatic first-pass)'"`UNIQ--ref-0000001C-QINU`"' (1) · ~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"' (1) · ~25% (oral; food does not affect absorption)'"`UNIQ--ref-0000005A-QINU`"' (1) · ~37% (oral; food does not affect)'"`UNIQ--ref-00000A23-QINU`"' (1) · ~64-90% (oral; increases at higher doses and with multi-day dosing)'"`UNIQ--ref-000008E9-QINU`"' (1) · ~77% (oral; not affected by food or antacids)'"`UNIQ--ref-0000011E-QINU`"' (1) · ~93% (oral)'"`UNIQ--ref-00000ED4-QINU`"' (1)

None (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-00000AF0-QINU`"' (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-0000005B-QINU`"' (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000A24-QINU`"' (1) · Generally considered safe; widely used in obstetric reflux.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021. Use individualized; lactation generally avoided.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Previously Category X; FDA removed the blanket statin contraindication in pregnancy in 2021.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Widely used in obstetric reflux; reassuring data.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

OTC (20 mg, 14-day course) and [[USLegal:Prescription only|Rx-only]] (higher and longer durations) in US (1) · [[USLegal:Prescription only|Rx-only]] in US (7)

Showing below up to 8 results in range #1 to #8.